首页> 外文期刊>Acta Anaesthesiologica Scandinavica >Adding sufentanil to levobupivacaine or ropivacaine intrathecal anaesthesia affects the minimum local anaesthetic dose required.
【24h】

Adding sufentanil to levobupivacaine or ropivacaine intrathecal anaesthesia affects the minimum local anaesthetic dose required.

机译:在左旋布比卡因或罗哌卡因鞘内麻醉中添加舒芬太尼会影响所需的最小局部麻醉剂量。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: We carried out this prospective, randomized, double-blind study in order to evaluate whether the intrathecal addition of sufentanil 3.3 mcg affects both the minimum local anaesthetic dose (MLAD) of spinal levobupivacaine and ropivacaine for a caesarean section and enhances the spinal block characteristics. METHODS: One hundred and eighty women were randomly allocated into four groups: levobupivacaine (Group L), levobupivacaine plus sufentanil (Group L+S), ropivacaine (Group R) and ropivacaine plus sufentanil (Group R+S). Each received 3 ml of the study solution intrathecally as part of a combined spinal/epidural technique. The initial dose was 12 mg for Groups L and L+S, and 15 mg for Groups R and R+S. The test solution was required to achieve a visual analogue pain score (VAPS) of 30 mm or less to be considered effective at skin incision, uterine incision, birth, peritoneal closure and at the conclusion of surgery. Effective or ineffective responses determined a 0.5 mg decrease or increase of the same drug, respectively, for the next patient in the same group, using an up-down sequential allocation. RESULTS: Using the Dixon and Massey formula, the MLAD was 10.65 mg [confidence interval (CI) 95%: 10.14-11.56] in Group L, 4.73 mg (CI 95%: 4.39-5.07) in Group L+S, 14.12 mg (CI 95%: 13.50-14.60) in Group R and 6.44 mg (CI 95%: 5.86-7.02) in Group R+S. CONCLUSIONS: The addition of sufentanil reduced the MLAD of both the local anaesthetics. It did not affect their potency ratio significantly and resulted in enhanced spinal anaesthesia.
机译:背景:我们进行了这项前瞻性,随机,双盲研究,以评估鞘内添加舒芬太尼3.3 mcg是否会影响剖宫产术中左旋布比卡因和罗哌卡因的最小局部麻醉剂量(MLAD),并增强脊髓阻滞。特征。方法:将180名妇女随机分为四组:左旋布比卡因(L组),左旋布比卡因加舒芬太尼(L + S组),罗哌卡因(R组)和罗哌卡因加舒芬太尼(R + S组)。每个患者在鞘内接受3 ml的研究溶液,作为脊柱/硬膜外联合技术的一部分。 L和L + S组的初始剂量为12 mg,R和R + S组的初始剂量为15 mg。需要测试溶液达到30 mm或更小的视觉模拟疼痛评分(VAPS),才能被认为对皮肤切口,子宫切口,出生,腹膜闭合和手术结局有效。有效或无效反应使用上下顺序分配,分别确定同一组中下一位患者减少或增加0.5 mg相同药物。结果:使用Dixon和Massey公式,L组的MLAD为10.65 mg [置信区间(CI)95%:10.14-11.56],L + S组的MLAD为4.73 mg(CI 95%:4.39-5.07),为14.12 mg R组(CI 95%:13.50-14.60)和R + S组6.44 mg(CI 95%:5.86-7.02)。结论:添加舒芬太尼可降低两种局部麻醉药的MLAD。它并没有显着影响其效价比,并导致了脊髓麻醉的增强。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号